Navigation Links
New, No-Swallow Fasprin(R) Reduces Problems Associated with Daily Aspirin Regimen
Date:11/13/2007

Fast-dissolve method uses the latest advancement in aspirin delivery

technology.

CLEVELAND, Nov. 13 /PRNewswire/ -- Improvita Health Products, Inc. has rolled out Fasprin(R), a patented, 81 milligram aspirin tablet that dissolves rapidly in the mouth instead of in the stomach, offering an effective, simplified solution for the millions of Americans who maintain a daily aspirin routine and worry about gastrointestinal bleeding or swallowing pills.

A daily low-dose aspirin therapy is commonly prescribed to adults to prevent heart attack and stroke and help improve blood flow to the heart. Small daily doses of aspirin have proven to be effective in reducing the chances of mini-strokes (in which clogged blood vessels prevent sufficient oxygen from reaching the brain). Aspirin is also used to reduce the risk of heart attack in people with clogged coronary arteries, and in those who've already had an attack.

With its great-tasting "citrus burst" flavor, Fasprin is ideal for patients on a daily heart health aspirin regimen and is sugar free for diabetics.

Fasprin's patented, no-swallow aspirin delivery method reduces irritation to the gastrointestinal tract by quickly dissolving in the mouth, which allows the aspirin to enter the blood stream in just three to five minutes, or up to ten times faster than conventional aspirin that typically is absorbed through the stomach.

Tom Klamet, president of Improvita Health Products, Inc., noted that the low-dose aspirin tablet uses the latest technology for delivering the required dosage to the blood stream. "Fasprin was developed by a physician who saw the many benefits of an aspirin that could be administered quickly and effortlessly," he commented. "A daily aspirin regimen can fast become a chore, especially for older adults who have a hard time swallowing a full tablet. Fasprin's ability to dissolve on the tongue ensures 100 percent bioavailability, or the delivery of the entire aspirin into the blood stream."

Some studies have shown that enteric-coated aspirin delivers just 50 percent of the dosage before the remaining tablet is eliminated by the body.

The quick-dissolve absorption also makes Fasprin the delivery of choice at the onset of a heart attack or stroke, where doctors recommend immediately administering aspirin. By doing so, aspirin can reduce the risk of death by as much as 23 percent, according to published studies.

Fasprin comes in a 30-tablet package (a month's supply), and carries a suggested retail price of $5.99. Fasprin is available wherever aspirin is sold, including Walgreens, CVS, Rite Aid, Albertsons, Meijer and Wal-Mart. The product is also available through the company's website at http://www.Fasprin.com.

[Product photos and additional stories available at http://www.improvita.com/fasprin-news.]

Contact:

Steve Corcoran

Vice President

Hybrid Marketing

Phone: 216-774-9274

Cell: 440-655-6073

corc@hybridmar.com

Tom Klamet

President

Improvita Health Products, Inc.

Phone: (216) 573-1850

tklamet@improvita.com


'/>"/>
SOURCE Improvita Health Products, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. New study: Pine bark reduces perimenopausal symptoms
2. Different method of evaluating the urinary tract system reduces radiation dose
3. Saline Reduces Mortality for Brain Injury Patients
4. New study: Pine bark extract reduces ADHD symptoms in children
5. Radiation therapy technique reduces length of prostate cancer treatment
6. Radiation therapy technique reduces length of prostate cancer treatment
7. MR spectroscopy identifies breast cancer, reduces biopsies
8. Body-mind meditation boosts performance, reduces stress
9. Parkinsons Institute research shows that nicotine reduces levodopa-induced dyskinesias
10. VIDEO from Medialink and EcoQuest: New Technology Reduces Exposure to MRSA Staph
11. Ranexa(R) Significantly Reduces Incidence of CV Death, MI or Recurrent Ischemia in MERLIN TIMI-36 Patients With Elevated BNP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: